Document Type : Original Article


1 Jr. Assistant Officer in Quality Assurance at Hetero, Unit V, Jadcherla, Mahabubnagar, Telangana, India

2 Smt. Sarojini Ramulamma College of Pharmacy, Seshadri Nagar, Mahabubnagar, Telangana, India

3 Pharm. D III year, Student, Smt. Sarojini Ramulamma College of Pharmacy, Sheshadri Nagar, Mahabubnagar, Telangana, India

4 Pharm. D V year, Student, Smt. Sarojini Ramulamma College of Pharmacy, Sheshadri Nagar, Mahabubnagar, Telangana, India


The purpose of the study was to evaluate the prevalence, co-morbidities, pharmacological therapy, and effectiveness of common lifestyle changes for metabolic dysfunction in women with the polycystic ovarian syndrome (PCOS) and related comorbidities in the gynaecology division. This 6-month prospective observational study of 120 PCOS patients who were gynaecology patients at a tertiary care hospital was conducted from September 2021 to February 2022. An interview with the patient was done using an assessment form. This study highlighted the supportive evidence among PCOS patients for the advantages of changing one's lifestyle. This study involved 90 PCOS individuals out of a total of 120 participants, many of them were in the 20–30 age group. This research analyses the high prevalence of cardiovascular disease co-morbidities and demonstrates that a high BMI is the most common risk factor for PCOS. The findings of our study indicate the necessity of evaluating the complications seen in individuals who are at risk, such as infertility. This line of research demonstrates the critical impact that medication and lifestyle modifications play in managing PCOS. Patients with the polycystic ovarian syndrome should get advice regarding lifestyle modifications from a clinical pharmacist.

Graphical Abstract

A study to assess the co-morbidities and complications of polycystic ovarian syndrome


Main Subjects

Selected author of this article by journal

ِDr. Neeli Sumanth
Sarojini Ramulamma College of Pharmacy


Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit:


Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.


Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 18%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.

[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.
[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.
[3] There is no limit to the number of words in a letter.
[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.
[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments

[7] Letters will be answered as soon as possible

  1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO (2016) Polycystic ovary syndrome. Nature reviews Disease primers 2 (1): 1-18. doi:
  2. Nandi A, Chen Z, Patel R, Poretsky L (2014) Polycystic ovary syndrome. Endocrinology and Metabolism Clinics 43 (1): 123-147. doi:
  3. Parsamanesh N, Moossavi M, Bahrami A, Butler AE, Sahebkar A (2018) Therapeutic potential of curcumin in diabetic complications. Pharmacological Research 136): 181-193. doi:
  4. Meier RK (2018) Polycystic ovary syndrome. Nursing Clinics 53 (3): 407-420. doi:
  5. Azziz R, Sanchez L, Knochenhauer E, Moran C, Lazenby J, Stephens K, Taylor K, Boots L (2004) Androgen excess in women: experience with over 1000 consecutive patients. The Journal of Clinical Endocrinology & Metabolism 89 (2): 453-462. doi:
  6. Sirmans SM, Parish RC, Blake S, Wang X (2014) Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. Journal of Investigative Medicine 62 (6): 868-874. doi:
  7. Foster C, Al-Zubeidi H (2018) Menstrual irregularities. Pediatric annals 47 (1): e23-e28. doi:
  8. Dunaif A, Fauser BC (2013) Renaming PCOS—a two-state solution. The Journal of Clinical Endocrinology & Metabolism 98 (11): 4325-4328. doi:
  9. Wang Z, Tang X, Yang S, Yin T, Zhao Y, Zheng A, Zhang R, Gu Y, Wang L (2019) A gradual change of chromosome mosaicism from placenta to fetus leading to T18 false negative result by NIPS. Clinica Chimica Acta 495): 263-268. doi:
  10. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK (2013) Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism 98 (12): 4565-4592. doi:
  11. Teede H, Tassone EC, Piltonen T, Malhotra J, Mol BW, Peña A, Witchel SF, Joham A, McAllister V, Romualdi D (2019) Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta‐analyses. Clinical endocrinology 91 (4): 479-489. doi:
  12. Menshawy A, Ismail A, Abdel-Maboud M, El-Din AA, Elgebaly A, Gadelkarim M, Bahbah EI, Abdelghany MF, Samy A, Abbas AM (2019) Effect of chlormadinone acetate versus drospirenone-containing oral contraceptives on the endocrinal features of women with polycystic ovary syndrome: Systematic review and meta-analysis of randomized clinical trials. Journal of Gynecology Obstetrics and Human Reproduction 48 (9): 763-770. doi:
  13. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM (2013) Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. Bmj 347): f5298. doi:
  14. Johnson NP (2014) Metformin use in women with polycystic ovary syndrome. Annals of translational medicine 2 (6): 56. doi:
  15. Gill H, Tiwari P, Dabadghao P (2012) Prevalence of polycystic ovary syndrome in young women from North India: A Community-based study. Indian journal of endocrinology and metabolism 16 (Suppl 2): S389–S392. doi:
  16. Barber TM, Hanson P, Weickert MO, Franks S (2019) Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clinical Medicine Insights: Reproductive Health 13): 1-9. doi:
  17. Gilbert EW, Tay CT, Hiam DS, Teede HJ, Moran LJ (2018) Comorbidities and complications of polycystic ovary syndrome: an overview of systematic reviews. Clinical endocrinology 89 (6): 683-699. doi:
  18. Palomba S, De Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC (2015) Pregnancy complications in women with polycystic ovary syndrome. Human reproduction update 21 (5): 575-592. doi:
  19. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY (2013) Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive Biology and Endocrinology 11 (1): 1-14. doi:
  20. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ (2019) Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2019 (3): Art. No. CD007506. doi: